ReportWire

Tag: oncology

  • Gloucester students rally for breast cancer patients

    The hallways were filled teachers, staff and students wearing T-shirts in shades of pink and emblazoned with white ribbons and the words “GHS Thinks Pink” at Gloucester High School on Friday — all in the name of breast cancer research.

    October is Breast Cancer Awareness Month, and a group of students sold those T-shirts to support cancer-related causes.


    This page requires Javascript.

    Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

    kAm~? uC:52J[ DEF56?ED 2?5 DE2776CD 82E96C65 😕 E96 7:6=5 9@FD6 E@ 7@C>65 2 9F>2? A:?< C:33@? 7@C E96 2??:G6CD2CJ @7 E96 D49@@=’D %9:?< !:?< qC62DE r2?46C C2==J]k^Am

    Source link

  • Huntington Hospital debuts $3M interventional radiology suite | Long Island Business News

    Huntington Hospital, part of the Northwell Health system, is now home to a renovated $3 million, 1,300-square-foot interventional radiology suite. The suite provides patients access to advanced, minimally invasive procedures that can diagnose and treat a wide range of conditions, often without the need for surgery, according to the hospital.

    Supported in part by philanthropic contributions, the suite is equipped with a Philips Azurion 7 M20 system, which offers high-resolution imaging designed to support physicians in delivering safer and more precise treatments.

    “Interventional radiology and interventional oncology are at the cutting edge of medical innovation and minimally invasive treatment,” Dr. Anthony Armetta, director of vascular and interventional radiology at Huntington Hospital, said in a news release about the suite.

    “With the addition of the new suite, we’re elevating the standard of care for our community to the very highest level,” Armetta added. “These advanced imaging capabilities allow us to treat complex conditions with greater accuracy and safety, often sparing patients from major surgery.”

    Interventional radiology and interventional oncology use advanced imaging – such as X-rays, CT scans, MRI and ultrasound – to guide minimally invasive treatments through a tiny incision. Compared to traditional surgery, these procedures typically offer faster recovery with same-day or next-day discharge, less pain and scarring, lower risk of complications, and access to image-guided treatments close to home, according to the hospital.

    The renovated lab offers minimally invasive treatments for a wide range of conditions. Services include cancer care with microwave ablation and Y-90 radioembolization; men’s and women’s health procedures such as prostate artery and uterine fibroid embolization; and treatments for vascular disease, including narrowed or blocked arteries, dialysis access and aortic aneurysms. The lab also provides emergency care for internal bleeding, removal of blood clots, placement of feeding tubes and medical ports, and relief of bile duct or urinary obstructions.

    “This investment underscores our commitment to bringing the very best medical care to the people of Huntington and the surrounding communities,” Dr. Nick Fitterman, president of Huntington Hospital, said in the news release. “From cancer treatments to emergency interventions, patients can now receive world-class, minimally invasive care close to home.”


    Adina Genn

    Source link

  • Women’s hockey tournament benefits cancer survivors

    Women’s hockey tournament benefits cancer survivors

    HAVERHILL — More than 500 women will hit the ice this weekend with a goal of raising money for cancer survivorship services in the Merrimack Valley.

    The annual Cross Check Cancer Women’s Hockey Tournament will take place from Aug. 9 to 11 at the Valley Forums in Haverhill and Lawrence. The cancer survivorship program is designed to help adults transition to a post-cancer life.

    Games will also be played at HockeyTown U.S.A .in Saugus.

    The women’s tournament was founded by Keri Capobianco in 2016. Capobianco started and runs the Women’s Hockey League of Boston, which calls Haverhill, Methuen and Peabody rinks home. The league is a place where women ages 18 to 60-plus of different skill levels can play hockey.

    The tournament is open to all women, who travel from all over New England to participate.

    All proceeds benefit Dana-Farber Cancer Institute’s Adult Survivorship Program, which offers those 21 years old and older access to services that help adult patients find expertise, education and any support they may need.

    Women who’ve survived cancer or are in treatment have participated in the event over the years, Capobianco said.

    She was drawn to supporting the Dana-Farber program because it’s designed to help people get back to their passions after cancer, whether that’s hockey or another activity. It also places an emphasis on nutrition, exercise and women’s health issues.

    The tournament’s creation was led by a grassroots effort by Capobianco and women from the WHL of Boston eight years ago. In 2016, they were happy to raise $5,200, Capobianco said.

    Now, there are 40 teams signed up for the three-day event and funds raised have grown each year since that first tournament. In 2023, the teams raised more than $65,000. To date, they’ve been able to donate $179,000 to the survivorship program.

    “It’s grown dramatically,” Capobianco said.

    “You don’t see that often where 100% of the proceeds goes to Dana Farber,” tournament participant Christine Ray said. “It’s amazing what Keri (Capobianco) has been able to do with this tournament, especially managing 40 teams at three different rinks.”

    Ray, 59, of Bolton, is one of the many women who travels each year to play in the tournament. She’s played in all eight tournaments so far and her team is ready for the next one.

    Ray first learned to skate at age 43 and has been hooked on hockey ever since. But the summer games mean more than lacing up the skates to her.

    “It’s so much more than hockey,” Ray said. “It gives women a chance to get together and reconnect and do some good at the same time.”

    Ray has known Capobianco for several years by playing hockey with her. Ray formed a tournament team in 2016 to support her friend and has watched as the fundraiser grew to hundreds of women bonding over their passion for the sport as a way to help the cancer community.

    “It’s supporting cancer survivors and being able to play hockey and doing something healthy for ourselves at the same time,” Ray said.

    The goal is to surpass last year’s fundraiser and cross the overall $250,000 mark in its ninth year.

    “We’re always trying to outdo ourselves,” Capobianco said. “We want to hit $70,000 this year.”

    The three rinks are sure to be busy as games are set from 9 a.m. to 10 p.m., but Capobianco said she wouldn’t have it any other way.

    The busyness means women are getting involved and doing their part to continue to benefit the mission of the tournament – cross check cancer.

    “Now we are able to connect these women who share the same passion for hockey and do some good in the world at the same time,” Capobianco said. “It’s a fantastic feeling.”

    By Angelina Berube | aberube@eagletribune.com

    Source link

  • Peabody cancer survivor rides for fellow patients

    Peabody cancer survivor rides for fellow patients

    PEABODY — It’s been 13 years since Peabody resident Robin Bernstein was diagnosed with cancer. Now cancer free, she’s riding in the Pan-Mass Challenge’s Winter Cycle for the sixth time to fight the terrible disease.

    “I want to let people know what I went through and that there’s hope,” said Bernstein, a 61-year-old legal assistant. “That’s the biggest thing: There’s hope. You’ve got to believe.”

    It was May 2012 when Bernstein became concerned by how much more frequently she was using the bathroom each day and noticed that her stomach was fully distended. The Tuesday after Memorial Day, a doctor’s visit turned into a sudden trip to the hospital for testing on a mass in her body.

    At 9:40 p.m. that night, her doctor shared news that she never expected: She had ovarian cancer.

    “I don’t know how I got home that night, but I did…” Bernstein said. “You can have all the money in the world, but if you don’t have your health, you have absolutely nothing.”

    Bernstein underwent surgery for a hysterectomy and to remove her appendix and the cancerous mass that June. When she woke up in little pain and without a colostomy bag following the surgery, she had a feeling everything was going to be OK.

    She was right. On July 3, 2012, Bernstein’s oncologist called her to let her know the cancer was Stage 1 and Grade 1A, meaning she wouldn’t need chemotherapy or radiation.

    “I walked outside of Starbucks, I sat on the ground and I bawled my eyes out. I thought I was going to have a heart attack,” Bernstein said. “Health is wealth.”

    Bernstein takes part in the Pan-Mass Challenge to support those who are still fighting their cancer and raise money for a cure.

    She’s participating in the organization’s PMC Winter Cycle on March 9 at Fenway Park. Along with hundreds of others, she’ll be riding a stationary bike and raising funds for Dana-Farber Cancer Institute.

    Participants have to raise a minimum of $400. Bernstein’s already raised about $2,100 from friends, colleagues and even current cancer patients.

    “One woman that lives on the North Shore, she’s got pancreatic cancer. She doesn’t have more than six months to live, and she’s one of the people that donated to my ride,” Bernstein said. “That’s pretty special.”

    As jarring as her diagnosis was, Bernstein counts herself as one of the lucky ones.

    “I just think how lucky am I to be sitting on a bike pedaling, listening to music? How lucky am I to be 12-and-a-half years cancer free?” she said.

    “There is hope. You’ve got to believe that eventually, there’s going to be a cure.”

    For more information on the Pan-Mass Challenge, visit www.pmc.org/. To donate to Bernstein’s ride, go to http://tinyurl.com/robinsridepmc.

    Contact Caroline Enos at CEnos@northofboston.com.

    By Caroline Enos | Staff Writer

    Source link

  • Health Alert Manhattan: Marijuana smoke is not safe. Doctor Explains | Kansas – Medical Marijuana Program Connection

    Health Alert Manhattan: Marijuana smoke is not safe. Doctor Explains | Kansas – Medical Marijuana Program Connection

    The Big Picture: Dr. Lindsay Boik-Price says, “We’ve got some misunderstandings that need fixing about daily cannabis smoking!”

    Doctor’s Expert Insights About Lung Health and Cannabis Smoke in Kansas

    Lung Health Alert for Manhattan

    MMP News Author

    Source link

  • YouTube to prohibit false claims about cancer treatments under its medical misinformation policy | CNN Business

    YouTube to prohibit false claims about cancer treatments under its medical misinformation policy | CNN Business


    New York
    CNN
     — 

    YouTube announced Tuesday that it will start removing false claims about cancer treatments as part of an ongoing effort to build out its medical misinformation policy.

    Under the updated policy, YouTube will prohibit “content that promotes cancer treatments proven to be harmful or ineffective, or content that discourages viewers from seeking professional medical treatment,” Dr. Garth Graham, head of YouTube Health, said in a blog post Tuesday.

    “This includes content that promotes unproven treatments in place of approved care or as a guaranteed cure, and treatments that have been specifically deemed harmful by health authorities,” he said, such as the misleading claim that patients should “take vitamin C instead of radiation therapy.”

    The update is just one of several steps YouTube has made in recent years to build out its medical misinformation policy, which also prohibits false claims about vaccines and abortions, as well as content that promotes or glorifies eating disorders.

    As part of the announcement, YouTube is rolling out a broader updated medical misinformation policy framework that will consider content in three categories: prevention, treatment and denial.

    “To determine if a condition, treatment or substance is in scope of our medical misinformation policies, we’ll evaluate whether it’s associated with a high public health risk, publicly available guidance from health authorities around the world, and whether it’s generally prone to misinformation,” Graham said. He added that YouTube will take action on content that falls into that framework and “contradicts local health authorities or the World Health Organization.”

    Graham said the policy is designed to preserve “the important balance of removing egregiously harmful content while ensuring space for debate and discussion.”

    Cancer treatment fits YouTube’s updated medical misinformation framework because the disease poses a high public health risk and is a topic prone to frequent misinformation, and because there is “stable consensus about safe cancer treatments from local and global health authorities,” Graham said.

    As with many social media policies, however, the challenge often isn’t introducing it but enforcing it. YouTube says its restrictions on cancer treatment misinformation will go into effect on Tuesday and enforcement will ramp up in the coming weeks. The company has previously said it uses both human and automated moderation to review videos and their context.

    YouTube also plans to promote cancer-related content from the Mayo Clinic and other authoritative sources.

    Source link

  • The Case for Lung Cancer Screening

    The Case for Lung Cancer Screening

     




    JULIA ROTOW: I’m Dr. Julia Rotow. I’m a thoracic medical oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts. So EGFR-mutated lung cancer is a subset of lung cancer diagnoses that’s most likely to affect younger individuals and individuals with a minimal or absent history of tobacco use.


    And this occurs in approximately 15% to 20% of lung cancer in this country. Overseas, for example, in Asian countries, that rate can be as high as 50% to 60%. So it’s an important subset of lung cancer to identify a diagnosis.

     

     


     




    JULIA ROTOW: So there are many risk factors for lung cancer. And it is correct that a history of tobacco use or current tobacco use is indeed a risk and does elevate the chances of lung cancer. That’s why lung cancer screening is so critical, particularly for those with this history.


    But that’s not the only risk for lung cancer. And in fact, lung cancer can also strike those you might not expect, so those, for example, without history of tobacco use, younger patients. And this is really where the data for EGFR mutations becomes critical.


    We know that for young people or people who never smoked with a diagnosis of lung cancer, their chance of having what’s called a driver mutation– mutation in their cancer that has caused this cancer to form– can be quite high. Over 50%– maybe even more than 75%– might have one. And these can be treated with targeted therapy pills in many circumstances.


    EGFR is the most common of these driver mutations. And as I said before, it’s most common in young people, young women, and in those of Asian descent.

     

     


     




    JULIA ROTOW: Current lung cancer screening guidelines, and here I’ll cite the US Preventive Services Task Force guidelines recommend lung cancer screening for those at high risk as defined by cumulative years of tobacco use and age. So the current guidelines, which released in 2021, recommend screening for those 50 and older, technically 50 to age 80 with at least a 20 pack-year history of tobacco use. And that means either one pack of cigarettes per day for 20 years, two packs per day for 10 years, and so on.



    And that’s considered to be high risk, and they recommend an annual low-dose screening CT scan. We know that by doing this screening, we can reduce the risk of death from lung cancer by catching lung cancer early when it’s more treatable. This improves survival.


    Unfortunately, in this country, uptake of lung cancer screening has been very low. And in many studies, only 15% to 30% of people who are eligible for lung cancer screening actually have this done. And that’s a real missed chance to catch lung cancers at an early stage particularly with all these different advances we’re seeing improving outcomes for early stage lung cancer.

     

     






    JULIA ROTOW: The first step is to speak with your primary care doctor. It’s a great opportunity to have a conversation about whether lung cancer screening might be helpful for you as an individual. And our physicians really enjoy speaking with their patients about this to help reduce their risk, just as you might talk about colonoscopies, or mammograms, or prostate cancer screening.


    Now, our current lung cancer screening guidelines don’t catch everyone who might be high risk, and there are some abstracts and presentations at ASCO this year that are getting to that point. For example, we know there are racial and ethnic disparities in both access to lung cancer screening and eligibility for screening based on current guidelines. And there are ongoing efforts to try to offer more risk-adaptive scores or risk-adaptive strategies to try to understand a lung cancer risk.


    I’d like to highlight a lung cancer screening study being presented at this year’s ASCO being led by Dr. Elaine Xu at NYU. And this study looks at instituting lung cancer screening with three annual CT chest scans in young Asian women who never smoked. So starting at age 40, even younger than our standard guidelines, and in people who never smoked or very minimally smoked– again, an unusual population for our wider national guidelines.


    And this speaks to the high risk of lung cancer mortality and Asian-Americans. It’s the leading cause of cancer death for this population. They have a higher rate of these actionable driver mutations, like EGFR in their cancers.



    And at this ASCO, Dr. Xu will be presenting in an upcoming session some preliminary results from the first 200 patients who enrolled on the study. And here they found a 1.5% rate of lung cancer in this young, non-smoking patient population. And all of the lung cancers they identified were EGFR mutated and were able to go on to receive adjuvant EGFR-targeted therapy. So it speaks to the importance of not just thinking about our traditional high risk patient population, who should absolutely get 100% screening if we could achieve it, but also these other less-common patient populations who can still benefit from potential screening strategies.

     

     


     




    JULIA ROTOW: EGFR is a protein that sits within tumor cells. It’s called the epidermal growth factor. And when active, it tells cells to grow and divide. In lung cancer cells, that can be made abnormally active by having a mutation which causes it to turn on when it should not. And this, we know, helps to drive lung cancer formation and growth and survival. And this is by targeting EGFR with EGFR inhibitors, which can shut down that protein and stop that survival signal, can improve outcomes for patients with this subtype of lung cancer.


    So for people diagnosed with an early stage lung cancer, so a lung cancer that might be able to be removed surgically with intent to cure, there are a number of different treatments that can be offered before or after surgery to try to reduce the risk of relapse and improve survival.


    These include what’s called neoadjuvant therapy, So presurgical therapy, usually chemotherapy or immunotherapy, for example, immune stimulating drugs; or adjutant therapy. And that’s post-operative therapy, so therapy after recovery from surgery that is similarly meant to reduce risk of relapse in the future.



    WebMD Health News


    © 2023 WebMD, LLC. All rights reserved.

    Source link

  • Breast density changes over time could be linked to breast cancer risk, study finds | CNN

    Breast density changes over time could be linked to breast cancer risk, study finds | CNN



    CNN
     — 

    Breast density is known to naturally decrease as a woman ages, and now a study suggests that the more time it takes for breast density to decline, the more likely it is that the woman could develop breast cancer.

    Researchers have long known that women with dense breasts have a higher risk of breast cancer. But according to the study, published last week in the journal JAMA Oncology, the rate of breast density changes over time also appears to be associated with the risk of cancer being diagnosed in that breast.

    “We know that invasive breast cancer is rarely diagnosed simultaneously in both breasts, thus it is not a surprise that we have observed a much slower decline in the breast that eventually developed breast cancer compared to the natural decline in density with age,” Shu Jiang, an associate professor of surgery at Washington University School of Medicine in St. Louis and first author of the new study, wrote in an email.

    Breast density refers to the amount of fibrous and glandular tissue in a person’s breasts compared with the amount of fatty tissue in the breasts – and breast density can be seen on a mammogram.

    “Because women have their mammograms taken annually or biennially, the change of breast density over time is naturally available,” Jiang said in the email. “We should make full use of this dynamic information to better inform risk stratification and guide more individualized screening and prevention approaches.”

    The researchers, from Washington University School of Medicine in St. Louis and Brigham and Women’s Hospital in Boston, analyzed health data over the course of 10 years among 947 women in the St. Louis region who completed routine mammograms. A mammogram is an X-ray picture of the breast that doctors use to look for early signs of breast cancer.

    The women in the study were recruited from November 2008 to April 2012, and they had gotten mammograms through October 2020. The average age of the participants was around 57.

    Among the women, there were 289 cases of breast cancer diagnosed, and the researchers found that breast density was higher at the start of the study for the women who later developed breast cancer compared with those who remained cancer-free.

    The researchers also found that there was a significant decrease in breast density among all the women over the course of 10 years, regardless of whether they later developed breast cancer, but the rate of density decreasing over time was significantly slower among breasts in which cancer was later diagnosed.

    “This study found that evaluating longitudinal changes in breast density from digital mammograms may offer an additional tool for assessing risk of breast cancer and subsequent risk reduction strategies,” the researchers wrote.

    Not only is breast density a known risk factor for breast cancer, dense breast tissue can make mammograms more difficult to read.

    “There are two issues here. First, breast density can make it more difficult to fully ‘see through’ the breast on a mammogram, like looking through a frosted glass. Thus, it can be harder to detect a breast cancer,” Dr. Hal Burstein, clinical investigator in the Breast Oncology Center at Dana-Farber Cancer Institute, who was not involved in the new study, said in an email. “Secondly, breast density is often thought to reflect the estrogen exposure or estrogen levels in women, and the greater the estrogen exposure, the greater the risk of developing breast cancer.”

    In March, the US Food and Drug Administration published updates to its mammography regulations, requiring mammography facilities to notify patients about the density of their breasts.

    “Breast density can have a masking effect on mammography, where it can be more difficult to find a breast cancer within an area of dense breast tissue,” Jiang wrote in her email.

    “Even when you take away the issue of finding it, breast density is an independent risk factor for developing breast cancer. Although there is lots of data that tell us dense breast tissue is a risk factor, the reason for this is not clear,” she said. “It may be that development of dense tissue and cancer are related to the same biological processes or hormonal influences.”

    The findings of the new study demonstrate that breast density serves as a risk factor for breast cancer – but women should be aware of their other risk factors too, said Dr. Maxine Jochelson, chief of the breast imaging service at Memorial Sloan Kettering Cancer Center in New York, who was not involved in the study.

    “It makes sense to some extent that the longer your breast stays dense, theoretically, the more likely it is to develop cancer. And so basically, it expands on the data that dense breasts are a risk,” Jochelson said, adding that women with dense breasts should ask for supplemental imaging when they get mammograms.

    But other factors that can raise the risk of breast cancer include having a family history of cancer, drinking too much alcohol, having a high-risk lesion biopsied from the breast or having a certain genetic mutation.

    For instance, women should know that “density may not affect their risk so much if they have the breast cancer BRCA 1 or 2 mutation because their risk is so high that it may not make it much higher,” Jochelson said.

    Some ways to reduce the risk of breast cancer include keeping a healthy weight, being physically active, drinking alcohol in moderation or not at all and, for some people, taking medications such as tamoxifen and breastfeeding your children, if possible.

    “Breast density is a modest risk factor. The ‘average’ woman in the US has a 1 in 8 lifetime chance of developing breast cancer. Women with dense breasts have a slightly greater risk, about 1 in 6, or 1 in 7. So the lifetime risk goes up from 12% to 15%. That still means that most women with dense breasts will not develop breast cancer,” Burstein said in his email.

    “Sometimes radiologists will recommend additional breast imaging to women with dense breast tissue on mammograms,” he added.

    The US Preventive Services Task Force – a group of independent medical experts whose recommendations help guide doctors’ decisions – recommends biennial screening for women starting at age 50. The task force says that a decision to start screening earlier “should be an individual one.” Many medical groups, including the American Cancer Society and Mayo Clinic, emphasize that women have the option to start screening with a mammogram every year starting at age 40.

    “It’s also very clear that breast density tends to be highest in younger women, premenopausal women, and for almost all women, it tends to go down with age. However, the risk of breast cancer goes up with age. So these two things are a little bit at odds with each other,” said Dr. Freya Schnabel, director of breast surgery at NYU Langone’s Perlmutter Cancer Center and professor of surgery at NYU Grossman School of Medicine in New York, who was not involved in the new study.

    “So if you’re a 40-year-old woman and your breasts are dense, you could think about that as just being really kind of age-appropriate,” she said. “The take-home message that’s very, very practical and pragmatic right now is that if you have dense breasts, whatever your age is, even if you’re postmenopausal – maybe even specifically, if you are postmenopausal – and your breasts are not getting less dense the way the average woman’s does, that it really is a reason to seek out adjunctive imaging in addition to just mammography, to use additional diagnostic tools, like ultrasound or maybe even MRI, if there are other risk factors.”

    Source link

  • A Florida woman spent her life savings on her daughter’s cancer treatment — then she won millions in the lottery | CNN

    A Florida woman spent her life savings on her daughter’s cancer treatment — then she won millions in the lottery | CNN



    CNN
     — 

    A Florida mother won $2 million in the lottery, just days after she finished paying off her daughter’s cancer treatment.

    Geraldine Gimblet, a resident of Lakeland, Florida, won $2 million from a $10 scratch-off lottery ticket, according to a news release from the Florida Lottery. She claimed her winnings as a one-time lump-sum payment of $1,645,000 last Friday, the April 7th news release says.

    Gimblet told the Florida Lottery she bought the last lottery ticket at her local gas station.

    “At first, the gas station clerk thought there were no tickets left,” she recalled, according to the news release. “But I asked him to double check because I like the crossword games the best. He found the last one!”

    Her daughter, who isn’t identified in the news release, spoke about the significance of her mother’s win through tears, the lottery said. Her mother paid for her treatment for breast cancer, she said.

    “The day before my mom bought this ticket, I rang the bell and walked out of the hospital after completing my last treatment for breast cancer,” said Gimblet’s daughter in the release. “My mom had taken out her life savings to take care of me when I was sick. I’m just so happy for her!”

    Gimblet purchased her lucky ticket at Pipkin Road Beverage Castle in Lakeland, according to the release. The retailer will also receive a $2,000 commission for selling the ticket.

    The chances of winning the $2 million prize in the “Bonus Cashword” game are just 1 in 3,921,270, according to the Florida Lottery’s website.

    Source link

  • Federal judge says insurers no longer have to provide some preventive care services, including cancer and heart screenings, at no cost | CNN Politics

    Federal judge says insurers no longer have to provide some preventive care services, including cancer and heart screenings, at no cost | CNN Politics



    CNN
     — 

    A federal judge in Texas said Thursday that some Affordable Care Act mandates cannot be enforced nationwide, including those that require insurers to cover a wide array of preventive care services at no cost to the patient, including some cancer, heart and STD screenings, and tobacco programs.

    In the new ruling, US District Judge Reed O’Connor struck down the recommendations that have been issued by the US Preventive Services Task Force, which is tasked with determining some of the preventive care treatments that Obamacare requires to be covered.

    The decision applies to task force recommendations issued on or after March 23, 2010 – the day the Affordable Care Act was signed into law. While the group had recommended various preventive services prior to that date, nearly all have since been updated or expanded.

    O’Connor’s ruling comes after the judge had already said that the task force’s recommendations violated the Constitution’s Appointments Clause. The judge also deemed unlawful the ACA requirement that insurers and employers offer plans that cover HIV-prevention measures such as PrEP for free.

    Other preventive care mandates under the ACA remain in effect.

    The full extent of the ruling’s impact and when its effects could be felt are unclear.

    It is likely the case will be appealed, and the Justice Department has the option to ask that O’Connor’s ruling be put on pause while the appeal is litigated.

    The Justice Department did not immediately respond to a CNN request for comment, nor did the US Department of Health and Human Services.

    White House spokesperson Karine Jean-Pierre called the case “yet another attack on the Affordable Care Act” and said that DOJ and HHS were reviewing Thursday’s ruling.

    The decision, in a case brought by employers and individuals in Texas, represents the latest legal affront to the landmark 2010 health care law. It is unclear what immediate practical effect O’Connor’s new ruling will have for those with job-based and Affordable Care Act policies because insurance companies will likely continue no-cost coverage for the remainder of the contracts even though the Obamacare requirements in question have been blocked. Contracts often last one calendar year.

    O’Connor’s Thursday ruling is expected to kick off a new phase of the legal battle over Obamacare’s preventive care measures. The judge rejected other claims that the ACA’s foes brought against the law – including challenges to the entities that determine no-cost coverage mandates for vaccines, an assortment of women’s health preventive care treatments, and services for infants and children. It’s possible that the plaintiffs appeal those aspects of O’Connor’s handling of the case, which could put at risk coverage requirements for additional preventive services at no cost.

    A lawyer for the challengers did not respond to CNN’s inquiry about Thursday’s decision.

    O’Connor is a George W. Bush-appointee who sits in the Northern District of Texas and who has issued anti-Obamacare rulings in major challenges to the law in the past. An appeal of the current case would head to the 5th US Circuit Court of Appeals, perhaps the most conservative federal appeals court in the country.

    While the case does not pose the existential threat to the Affordable Care Act that previous legal challenges did, legal experts say that O’Connor’s ruling nonetheless puts in jeopardy the access some Americans will have to a whole host of preventive treatments.

    “We lose a huge chunk of preventive services because health plans can now impose costs,” said Andrew Twinamatsiko, associate director of the O’Neill Institute for National and Global Health Law at Georgetown University. “People who are sensitive to cost will go without, mostly poor people and marginalized communities.”

    Thursday’s ruling, if left standing, could have significant consequences for Americans nationwide by limiting access to key preventive services aimed at early detection of diseases, including lung and colorectal cancer, depression and hypertension.

    Some of the US Preventive Services Task Force’s recommendations – including lung and skin cancer screenings, the use of statins to prevent cardiovascular disease and the offer of PrEP for those at high risk of HIV – were issued after the ACA’s enactment.

    Certain older recommendations have been updated with new provisions, such as screening adults ages 45 to 49 for colorectal cancer.

    “It would effectively lock in place coverage of evidence-based prevention with no cost sharing from 13 years ago,” said Larry Levitt, executive vice president for health policy at the Kaiser Family Foundation.

    Some of the cost-sharing for these preventive services can be substantial. PrEP, for instance, can cost up to $20,000 a year, plus lab and provider charges, according to Kaiser.

    In an earlier ruling, the judge upheld certain free preventive services for children, such as autism and vision screenings and well-baby visits, and for women, such as mammograms, well-woman visits and breastfeeding support programs.

    O’Connor also upheld the mandate that provides immunizations at no charge for the flu, hepatitis, measles, shingles and chickenpox.

    These services are recommended by the Health Resources and Services Administration and the Advisory Committee on Immunization Practices.

    Insurers will have to continue to cover preventive and wellness services since they are one of the Affordable Care Act’s required essential health benefits. But under O’Connor’s ruling, they could require patients to pick up part of the tab.

    Insurers’ trade associations stressed there would be no immediate disruption to coverage.

    “It is vitally important for patients to know that their care and coverage will not change because of today’s court decision,” said David Merritt, senior vice president of policy and advocacy for the Blue Cross Blue Shield Association. “Blue Cross and Blue Shield companies strongly encourage their members to continue to access these services to promote their continued well-being. We will continue to monitor further developments in the courts.”

    More than 150 million people with private insurance can receive preventive services without cost-sharing under the Affordable Care Act, according to a 2022 report published by HHS.

    Overall, about 60% of the 173 million people enrolled in private health coverage used at least one of the ACA’s no-cost preventive services in 2018 prior to the Covid-19 pandemic, according to a recent Kaiser analysis. These include some services that will continue to be available at no charge under the judge’s ruling.

    The most commonly received preventive care includes vaccinations, not including Covid-19 vaccines, well-woman and well-child visits, and screenings for heart disease, cervical cancer, diabetes and breast cancer, according to Kaiser. The most commonly used preventive services will continue to be covered at no cost.

    Studies have shown the Obamacare mandate prompted an uptake in preventive services and narrowed care disparities in communities of color.

    “There’s plenty of evidence that people responded to this incentive and started using preventive care more often,” said Paul Shafer, assistant professor of health policy at Boston University.

    This story has been updated with additional details.

    Source link

  • Care and Comfort During Stage III or IV Breast Cancer Treatment

    Care and Comfort During Stage III or IV Breast Cancer Treatment

    “Advanced breast cancer doesn’t have to be a journey taken alone,” says Sony Sherpa, MD, a holistic doctor in Sacramento, CA. “Thankfully, you have vast support options and resources available to you.”

    Your Doctor and Medical Team

    Many cancer centers have a system of support in place that includes your doctor and other health care professionals. Keep in mind that they can’t help if you don’t share what’s going on. To get the support you need, be open with your questions and concerns.

    “Sometimes patients don’t ask questions because they don’t want to bother their doctor or nurse, or they don’t think their questions are that important,”says Rebecca Crane-Okada, PhD, director of Cancer Navigation & Willow Sage Wellness Programs at the Margie Petersen Breast Center at Providence Saint John’s Health Center in Santa Monica, CA. “But your doctor is really the first place to start.” 

    If your doctor or medical team doesn’t seem to listen to you or respect your questions, or you’re not confident they have enough experience with advanced breast cancer, look for a new team.

    Social Workers and Counselors

    “Social workers, psychologists, marriage and family therapists, or licensed professional counselors help with grief and loss, coping and adjustment, and family communication,” says Crane-Okada. They may also have techniques to help you with symptoms like insomnia.

    They may also help with practical things like housing, transportation, insurance, and financial aid questions. They may connect you with other resources and services, such as:

    • Financial help
    • Where and how to get a wig if you’d like one
    • Help with problems that come up at work
    • Insurance issues
    • Transportation to medical appointments

    Ask your doctor or cancer center for a referral. “Many cancer centers and hospitals now provide oncology social workers and counselors who can help you cope with the psychological, physical, and emotional impact of a cancer diagnosis,” Sherpa says.

    Spiritual Support

    Spiritual leaders and faith-based communities can offer comfort and support. They may help with practical things to make your daily life easier, like chores, meals, and transportation. They may also make you feel less alone and more supported. “A chaplain may be available to help with spiritual or religious concerns or questions,” says Crane-Okada.

    Friends and Family

    Don’t be afraid to reach out and ask for help. Friends and family often want to help, but they’re not always sure what you need or what to offer. Try to be specific about what things they can do that will make your life easier and better.

    For example, ask family and friends if they can drive you to appointments, watch your kids, help with groceries, or to simply be a shoulder to lean on.

    Support Groups and Communities

    Consider joining a support group, which may be led by an oncology social worker. They’re a great way to connect with other people going through a similar experience. They can also help you feel less alone, find valuable information, and learn new ways to cope. You can find support groups in local hospitals, cancer centers, community organizations, and online. Try the Komen Metastatic Breast Cancer group or search Facebook for metastatic breast cancer groups.

    Online Resources

    The amount and types of support you can get from nonprofit organizations and online resources is vast, Crane-Okada says. It ranges from toll-free helplines to information about your diagnosis and treatment to one-on-one counseling services you can get through teletherapy.

    Try these online resources:

    • American Cancer Society
    • National Cancer Institute
    • Patient Advocate Foundation
    • National Coalition of Cancer Survivorship
    • Cancer Support Community
    • Cancer Care
    • Cancer Net

    Palliative Care

    You can have palliative care no matter your age, type, or stage of cancer. It’s for anyone who wants to feel better, manage symptoms, and get support with non-medical needs. 

    Talk to your doctor about your palliative care options before you start treatment. Palliative care often works best when you start it right after you’re diagnosed and before treatment. If you have palliative care during treatment, you may have less severe symptoms and a better quality of life.

    Self-Care

    There’s a lot you can do to support yourself as you manage advanced breast cancer.

    Stay healthy. Eat well. Limit how much alcohol you drink. Avoid smoking. Manage stress the best you can. Stay on top of your medical checkups and tests.

    Exercise regularly. Being physically active can help you feel stronger, boost your energy, and lower stress. It may also give you a sense of accomplishment and control. Talk to your health care team to create an exercise plan that works you.

    Follow through with rehabilitation. If your doctor recommends cancer rehabilitation, you may have physical therapy, occupational therapy, pain management, nutritional planning, career counseling, or emotional counseling. These are helpful resources that can help you get more control of your life and stay independent.

    Take care of what’s on your mind. If there’s something that feels unresolved in your life, taking care of it now can give you peace of mind. Consider facing whatever it is that’s making you feel bad. Maybe you want to fix a broken relationship with a family member or friend. Maybe you’re worried about getting your will and advance directive in place. These things can weigh on your mind, so it’s helpful to take care of them if you feel up to it.

    Source link

  • A lot of people hide their cancer diagnosis from their bosses. These companies aim to change that | CNN Business

    A lot of people hide their cancer diagnosis from their bosses. These companies aim to change that | CNN Business



    CNN
     — 

    After having surgery to remove a small cancerous tumor from his neck last year, Publicis Groupe CEO Arthur Sadoun decided to tell his employees, clients and shareholders of his condition. He still needed to undergo radiation and chemotherapy, and explained to them what that would mean for his work schedule.

    While deciding to go public was difficult for Sadoun because it meant showing vulnerability both as a person and as a leader of one of the world’s largest advertising agencies, he said he received thousands of compassionate responses from both inside and outside Publicis after doing so.

    What shocked him most, he said, was how many people told him they hid their own cancer diagnosis from their employers for fear of losing their job or being perceived as weak. Instead, they took vacation days for treatments or scheduled very early morning procedures so they could work the same day, Sadoun told CNN. Some even hid their children’s cancer treatments from their boss, he added.

    “That is crazy,” Sadoun said. “I started 2022 with cancer and left it with a mission.”

    That mission is to create a worldwide campaign to encourage employers to eradicate the stigma and anxiety of having cancer at work.

    The initiative — called the #WorkingWithCancer Pledge — launched Tuesday at the 2023 World Economic Forum in Davos, Switzerland.

    Many of the world’s best-known companies have agreed to the pledge already. They include Bank of America, Citi, Disney, Google, L’Oréal, Marriott, McDonald’s, Meta, Microsoft, Nestlé, PepsiCo, Toyota, Unilever and Walmart.

    Employers who take the pledge promise “to abolish job fear and insecurity that exist for cancer sufferers in the workplace.”

    Signatories also pledge to do a better job publicizing to their workforces the benefits they already have in place for employees with cancer and for employees taking care of a family member with cancer. They will also consider ways to do more.

    Walmart, for instance, notes on the #WorkingWithCancer Pledge site that it currently offers access to high-quality care in the United States through its Centers for Excellence Program, and that the care is often free for employees, including travel and lodging if necessary for both the employee and their caregiver. The company also said it provides free counseling with a licensed therapist, educational resources and experts on cancer, as well as leave-of-absence programs.

    In terms of forward-looking pledges, Publicis is committing to its employees worldwide that it will:

    • Secure the job and salary of any employee suffering from cancer for at least 1 year so they can focus on their health treatment
    • Offer career support to any affected employee after they return to work to help them assess whether they wish to do the same job or try something different, depending on their capacities after treatment
    • Provide affected employees with an internal community of trained volunteers who can offer support “so that our employees don’t feel alone at a challenging time”
    • Offer custom support to employees serving as caregivers to a family member with cancer so they can get what they need in terms of flexibility and time to both “maintain their energy at work and as a caregiver.”

    Leading cancer institutions, including Memorial Sloan Kettering, are backing Sadoun’s initiative.

    His hope is that if the world’s biggest companies go public with what they are doing both to help employees with cancer and to make it easier to talk about it at work, smaller companies may follow their lead.

    Given how prevalent cancer diagnoses are — and how, thanks to improved treatments and early detection, it can be more of a chronic disease than a death sentence in many instances — “Not only will we have to live with [cancer],” Sadoun said, “we will have to work with it.”

    Source link

  • Rebirth: Cancer Reshapes Nurse’s Life, Outlook, and Career

    Rebirth: Cancer Reshapes Nurse’s Life, Outlook, and Career

    Oct. 20, 2022 — Tawny Roeder was 23 years old and 3 months away from getting her nursing degree at Briar Cliff University in Sioux City, IA, when she got a job as a training nurse. She was ready to take on the world, but first she had to clear an obstacle: She felt she lacked empathy for the patients in the oncology unit where she worked.

    “I knew no one with cancer at the time,” she says. “It hadn’t really impacted my life too much, so it was daunting to have to work with those patients.” 

    In one word, she felt “oblivious” about the struggles these patients experience. “I felt like I didn’t have the words to care for these people. It was something that scared me.”

    She was also oblivious to something far scarier that lurked in her young life. She was on the dance team at Briar Cliff, and “I should have been in the best shape of my life,” but she found her energy and wind spent too easily. 

    At home during the 2008 spring break, her mom noticed her breathing difficulty. She also began having back pain that woke her up at night.

    An X-ray showed a huge mass on her lung. Roeder got the results of a subsequent biopsy – lymphoma — over the phone, “which was awful. I was alone in my apartment.”

    Just 2 weeks after starting to care for cancer patients in her hospital, Roeder became one. She studied for her nursing exams while undergoing chemotherapy with the help of her workmates. 

    Roeder’s journey was just beginning, though. She was diagnosed with an aggressive form of diffuse large B-cell lymphoma, a life-threatening blood cancer. 

    “There are several patients exactly like Tawny who are on their way to living when they are hit with this deal-breaker,” says Manali Kamdar, MD, clinical director of lymphoma services for University of Colorado Medicine. The diagnosis creates “a huge break in what happens in living a normal life.”

    Roeder is one of 80,000 Americans diagnosed yearly with non-Hodgkin’s lymphoma, the most common form of lymphoma. 

    Kamdar says Roeder’s is one of 85 different subtypes, and she emphasizes that“it is absolutely important that patients get that subtype.” Sometimes it takes several tests, she says, but it is important to establish the subtype as this may influence management of the disease.  

    Kamdar also says there are now many different treatment options. Chemotherapy with the addition of medications has been a backbone of therapy, but now there are also chemo-free treatment options as well as approaches that involve genetically modifying a patient’s own immune cells, she says. 

    “The last 3 years have seen a sea change with the number of treatments that have been approved for patients with lymphoma. What I had in my toolkit 5 years ago is nothing compared to what I have today,” she says. 

    Roeder learned quickly that her cancer was so aggressive that she would need a stem cell transplant, during whichher healthy cells werecollected and stored while she underwent high-dose chemo, and would then be put back into her body intravenously. 

    However, thistreatment was not available in Sioux City. The closest center was in Omaha, NE, about a 90-minute drive away.

    “I was absolutely terrified,” Roeder says. She and her then-boyfriend, Cody, decided to uproot from Sioux City and move to Nebraska. “We thought it might as well be a good place for us to get jobs.”

    After a monthlong stay in the hospital while she underwent intensive treatment involving chemo and stem cell therapy, she eventually returned home. She now marks Sept. 11, 2008, as her “rebirth” after the treatment. 

    The night she returned, Cory proposed to her. “That was a very great coming-home surprise,” she says. “I had tubes hanging out of me. I was bald. I’m not sure it was the most romantic moment.”

    The couple married the following May. Meanwhile, Roeder had started her nursing career in pediatrics, but “every time I would go to my oncology checkup, the doctor would say, ‘Come work for our team.’” 

    In 2011, she took her oncologist up on the offer and began working as a staff nurse in the oncology unit at the University of Nebraska Medical Center.

    “It just kind of clicked,” she says. “This is probably why I’m still here. You sometimes have that survivor’s guilt as to why some survive and others don’t.”

    Roeder’s treatment left her unable to bear children, so she and Cody have adopted a boy and a girl. 

    Now 37, in addition to working with lymphoma patients, she also volunteers for the Lymphoma Research Foundation to raise awareness and funding to fight the disease. “I have gained a lot of friendships — people I’ve been in contact with just because of their transplants,” she says.

    Roeder, who has been cancer-free since, is now the case manager for lymphoma patients undergoing transplants. She inspires her new patients, especially those who feel alone in their disease journey. “Most are very shocked” when they hear her story, she says. “It’s really shocking for people to see that I look healthy. One hundred percent of the time it is well-received and very much appreciated.”

    Source link

  • Study Demonstrates Impact of CME Activities on Clinician Awareness of Biosimilars

    Study Demonstrates Impact of CME Activities on Clinician Awareness of Biosimilars

    Press Release



    updated: Jun 21, 2019

    ​​The outcomes of a recent continuing medical education (CME) program, the results of which were published in the June 20 issue of Evidence-based Oncology in an article titled “Addressing Oncologists’ Gaps in the Use of Biosimilar Products,” demonstrated that, prior to participating in the education activity, only 22% of oncology healthcare providers (HCPs) knew the basic aspects of biosimilars, i.e. how biosimilars differ from generic drugs and the requirements for FDA approval. Following completion of the education, knowledge of biosimilars increased 56% (from 22% to 78%). The educational program demonstrated not only the need for continued efforts to educate healthcare providers about biosimilars but also demonstrated the ability of education to effectively address the current gaps among HCPs in using biosimilars. The study was based on the results from a Rockpointe-developed educational initiative, “From Biologics to Biosimilars in Oncology Practice: A New Source of Value,” deployed in 2017 and 2018 with the goal of better preparing medical oncologists, hematologists, nurses, pharmacists and other clinicians to incorporate biosimilars into the treatment paradigm for patients with cancer. The initiative consisted of expert-led, interactive CME activities, based on a core curriculum and presented as a series of three live meetings and an online course.

    Both the live and online activities featured a slide-based lecture with interactive multiple-choice questions. A total of 9,599 individuals participated in the activities, including 114 during regional meetings and 9,485 in an online webcourse. To measure the impact of the education, each question was posed twice: once before exposure to the education and once immediately after exposure. Live activity participants also were invited to complete an electronic follow-up survey, including the same questions at six to eight weeks after the event, to measure knowledge retention over time.

    Key study findings

    ·         In the aggregate, scores on practice-impact questions improved from 22% at baseline to 78% during the post-test, with similar trends seen with the webcourse (23% to 78%) and the regional live meetings (27% to 81%).  In a survey, 60 days after completion of the education activity, close to half the learners (47%) reported competency with utilizing biosimilars in their practice.

    ·         After completion of the activity, significantly more participants understood the level of evidence needed for biosimilars to be approved by the FDA, representing 68% and 66% absolute increases among live meeting and webcourse attendees, respectively.

    ·         Prior to the activity, only 10% of live meeting attendees knew that a biosimilar must demonstrate no clinically meaningful differences with the reference biologic, in terms of safety, purity, and potency; this indicates the magnitude of the gap among community oncology clinicians in understanding the approval process for biosimilars.

    ·          Knowledge of the evidence leading to approval by the FDA of the biosimilar MYL-1401O (trastuzumab-dkst) for treating breast cancer increased significantly following both activities: 36% pre-test to 96% post-test in the live meetings, and 17% pre-test to 62% post-test in the webcourse (P<0.05).

    ·         Self-reported familiarity with the biosimilar approval process improved threefold, increasing from 21% at baseline to 69% immediately after the activity, while confidence in using biosimilars increased from 25% to 36% in pre- and post-activity measurements. The smaller rise in confidence in using biosimilars suggests that healthcare providers remain somewhat hesitant to integrate biosimilars into practice and that additional exposures to biosimilar education in this specific learner group should result in even greater uptake of knowledge, comprehension and competence.

    ·         Interestingly, none of the six barriers to the use of biosimilars that were queried were rated as major barriers by most participants. Institutional or formulary restrictions were most often cited as a major barrier (15%), followed by patient reluctance to use biosimilars (12%), lack of familiarity with the biosimilar approval process (12%), lack of efficacy data (11%), lack of safety data (11%), and other, including lack of time, cost of therapies, and insurance (10%).

    ·         Based on a 73.1% non-overlap between scores measured at baseline and at the end of the live activity, it is estimated that the 114 clinicians who participated in the regional meetings are 73.1% more likely to deliver evidence-based care for cancer, positively affecting the care of patients seen during 2,641 visits each month. Similarly, the webcourse was associated with a large effect size, with 81.1% nonoverlap between pre-test and post-test scores. It is estimated that the 9,485 clinicians who participated in the online activity are 81.1% more likely to deliver evidence-based care for cancer, positively affecting the care of patients seen during 55,345 visits each month.

    The study showed that educating clinicians on Biosimilars will increase the knowledge and familiarity with those providers, potentially seeing cost savings with similar outcomes across the board.

    To read the full study, go to https://www.ajmc.com/journals/evidence-based-oncology/2019/june-2019/addressing-oncologists-gaps-in-the-use-of-biosimilar-products.

    All activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME).

    Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, including implementing MIPS, combating the nation’s opioid crisis and utilizing technical advances that improve care. As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy and Medicine. At Rockpointe, education equals quality.

    Source: Rockpointe Corp

    Source link